The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Forecasted Rise In Market Size Of The Specific Antiviral Drugs For COVID 19 Market During The Forecast Period?
The market for specific antiviral drugs designed for COVID-19 has experienced swift expansion over recent years. It is projected to expand from $15.23 billion in 2025 to $17.83 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.1%. The growth witnessed during the preceding period stemmed from factors such as the swift global dissemination of COVID-19, the issuance of emergency use authorizations, continued dependence on established antiviral drug categories, constraints in worldwide production capacity, and elevated rates of hospitalization.
The market for specific antiviral drugs used to treat covid 19 is anticipated to experience substantial growth in the upcoming years. It is projected to reach $33.17 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 16.8%. Factors contributing to this growth during the forecast period include the advancement of next-generation antiviral medications, a rise in public-private collaborations, increased acceptance of preventive treatments, the broadening use of combination therapies, and the incorporation of personalized medicine strategies. Key trends anticipated during this period encompass escalating investment in covid-19 antiviral drug research and development, wider uptake of oral antiviral tablets, an increase in monoclonal antibody treatments, an expansion of both hospital and retail distribution networks, and a concentrated effort on targeted treatments for patients who are hospitalized or at high risk.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24713&type=smp
What Important Drivers Are Powering The Specific Antiviral Drugs For COVID 19 Market Growth?
An increase in COVID-19 infections is anticipated to boost the specific antiviral drugs for the COVID-19 market in the future. COVID-19 cases are defined as persons confirmed positive for the SARS-CoV-2 virus, the pathogen responsible for the disease. This surge in COVID-19 cases stems from the emergence of novel variants, characterized by increased transmissibility and a partial ability to bypass immunity acquired through vaccination or prior illness. These specific antiviral drugs for COVID-19 mitigate the illness’s intensity and length, leading to better patient outcomes and lessening the overall impact of COVID-19 infections. For example, the World Health Organization, a global public health agency based in Switzerland, reported in May 2025 that the Eastern Mediterranean region experienced a rise in its test positivity rate from 4% to 17% in early 2025, exceeding the rate from the corresponding period in 2024. Consequently, the escalating number of COVID-19 infections is a key factor driving the expansion of the specific antiviral drugs for the COVID-19 market.
How Are Different Segment Groups Identified Within The Specific Antiviral Drugs For COVID 19 Market?
The specific antiviral drugs for covid 19 market covered in this report is segmented –
1) By Type: Tablet, Injection
2) By Indication: Hospitalized Patients, Non-Hospitalized Patients, Preventive Treatment
3) By Drug Class: Nucleoside Analogues, Protease Inhibitors, Ribonucleic Acid Polymerase Inhibitors, Entry Inhibitors, Monoclonal Antibodies
4) By Route Of Administration: Oral, Intravenous, Subcutaneous, Inhalation
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Tablet: Oral Antiviral Tablets, Combination Antiviral Tablets, Extended-Release Tablets
2) By Injection: Intravenous (IV) Antiviral Injections, Intramuscular (IM) Antiviral Injections, Subcutaneous Antiviral Injections
Which Trends Are Contributing To Changes In The Specific Antiviral Drugs For COVID 19 Market?
Key players in the specialized antiviral drugs for the COVID-19 market are prioritizing the creation of groundbreaking treatments, particularly oral antiviral therapies, to boost both the availability and efficacy of care. Oral antiviral therapies refer to medicines ingested orally to halt the reproduction of viruses like COVID-19, thus presenting a convenient and potent treatment choice. For instance, in March 2024, Shionogi And Co., a pharmaceutical company based in Japan, introduced Xocova and received full standard approval for the antiviral drug ensitrelvir from Japan’s Ministry of Health, Labour and Welfare (MHLW). Moreover, it also delivers post-exposure prophylaxis by considerably lessening the chances of exposed individuals developing symptomatic COVID-19 and truncating symptom duration, along with a commendable safety profile.
Which Firms Are Competing In The Specific Antiviral Drugs For COVID 19 Market?
Major companies operating in the specific antiviral drugs for covid 19 market are Pfizer Inc., Merck & Co. Inc., Gilead Sciences Inc., Shionogi & Co. Ltd., Cipla Limited, Hetero Drugs Limited, Roche Holding AG, Johnson & Johnson, Novartis AG, GSK plc, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Beximco Pharmaceuticals Limited, Atea Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., RedHill Biopharma Ltd., Synairgen plc, Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Lupin Limited, Natco Pharma Ltd., Zydus Lifesciences Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Apotex Inc., Mylan N.V.
Access The Complete Specific Antiviral Drugs For COVID 19 Market Report:
Which Region Leads The Specific Antiviral Drugs For COVID 19 Market By Size?
North America was the largest region in the specific antiviral drugs for COVID 19 market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specific antiviral drugs for covid 19 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Specific Antiviral Drugs For COVID 19 Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=24713&type=smp
Browse Through More Reports Similar to the Global Specific Antiviral Drugs For COVID 19 Market 2026, By The Business Research Company
Antivirals Market Report 2026
https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report
The Antiviral And Antimicrobial Coatings Market Report 2026
Antiviral Combination Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model